Greatest International Antiinfective Trial With Avelox
Status:
Completed
Trial end date:
2007-11-01
Target enrollment:
Participant gender:
Summary
The observation period for each patient covered an initial treatment period with Avelox® plus
optional 2 long-term follow-up periods (6 and 12 months).For each patient, the physician
documented data at any initial visit (baseline) and at least one short-term follow-up visit
(=initial treatment period).Optionally, long-term follow-ups (6 and 12 months) were
documented, and a patient questionnaire was filled in.
Details
Lead Sponsor:
Bayer
Treatments:
Anti-Infective Agents Fluoroquinolones Moxifloxacin Norgestimate, ethinyl estradiol drug combination